Figure 5
From: Dual “mAb” HER family blockade in head and neck cancer human cell lines combined with photon therapy
Treatment impact on protein expression. The expression of phospho-EGFR (Tyr1068) (182 kDa), phospho-AKT (Ser473) (63 kDa) and phospho-MEK1/2(Ser217/221) (52 kDa) was evaluated under the following treatment conditions: control; cetuximab 5 nM; pertuzumab 20 μg/mL; cetuximab 5 nM + pertuzumab 20 μg/mL; 10 Gy; 10 Gy + cetuximab 5 nM; 10 Gy + pertuzumab 20 μg/mL; 10 Gy + cetuximab 5 nM + pertuzumab 20 μg/mL. Ratios of phospho-EGFR, phospho-AKT and phospho-MEK to GAPDH expression (41 kDa) were calculated and are graphed as (protein-of-interest (POI)/GAPDH). (A) SQ20B. (B) SQ20B-CSCs. (C) FaDu. Statistically significant differences are expressed as *p < 0.05, **p < 0.01 and ***p < 0.001. Each experiment was performed in triplicate.
